Deutsche Bank sets $65 target on Immunocore stock, rates Buy

Deutsche Bank initiated coverage on Immunocore (IMCR) with a Buy rating and a $65 price target, citing the potential of its ImmTAX platform and Tebentafusp (KIMMTRAK), now the standard of care for HLA-A02+ 1L metastatic Uveal Melanoma (mUM). Immunocore reported strong Q1 earnings, exceeding expectations with adjusted EPS of $0.10 and revenue of $93.9 million, driven by a 33% year-over-year increase in KIMMTRAK sales; expansion into other melanoma treatments and a potential patent extension to 2035 could provide further upside, though competition in first-line Cutaneous Melanoma remains high.

Analysis

Deutsche Bank has initiated coverage on Immunocore Holdings (NASDAQ:IMCR) with a Buy rating and a $65.00 price target, aligning with a robust analyst consensus highlighted by ten recent upward earnings estimate revisions. The company exhibits strong financial health, evidenced by an InvestingPro score of 3.18 out of 5 and robust liquidity metrics. Central to this positive outlook is Immunocore's ImmTAX platform and its lead therapy, Tebentafusp (KIMMTRAK), which has established itself as the standard of care for HLA-A02+ first-line metastatic Uveal Melanoma (mUM) due to a demonstrated overall survival (OS) benefit; notably, this OS improvement occurs even as objective response rate (ORR) and progression-free survival (PFS) were not significantly different, suggesting current radiological techniques may not fully capture the ImmTAC platform's efficacy in reducing circulating tumor DNA. Immunocore's recent first-quarter results surpassed expectations, with adjusted earnings per share of $0.10 (beating the anticipated -$0.39 by $0.49) and revenue of $93.9 million (exceeding the forecasted $86.1 million), largely fueled by a 33% year-over-year surge in KIMMTRAK net product sales. This performance contributed to a net income of $5.0 million for the quarter, a significant turnaround from a net loss of $24.4 million in the prior year, while research and development expenses slightly decreased to $56.5 million. The company maintains a healthy balance sheet with $837.0 million in cash, cash equivalents, and marketable securities, more cash than debt, and a current ratio of 6.36. Financially, Immunocore shows strong last-twelve-months revenue growth of 25.75% and an impressive gross profit margin of 96.68%. Future growth catalysts include the potential expansion of Tebentafusp into second-line and beyond Cutaneous Melanoma (mCM), with Phase 3 data expected in H2 2026, and a possible patent extension for Tebentafusp to 2035. Brenentafusp also presents modest expansion opportunities into Platinum Resistant Ovarian Cancer by 2026, though caution is advised for its application in first-line Cutaneous Melanoma due to high competitive benchmarks. Clinical trial progress remains on track, with TEBE-AM Phase 3 enrollment completion expected by H1 2026.

Key Decisions for Investors

• Given Deutsche Bank's Buy initiation, strong Q1 performance, KIMMTRAK's established market position, and upward analyst revisions, investors may consider IMCR an attractive investment, particularly with the stock's current valuation offering a favorable risk/reward scenario.
• Key catalysts to monitor include upcoming clinical trial data, especially Phase 3 results for Tebentafusp in mCM expected in H2 2026, and developments regarding the potential patent extension for KIMMTRAK to 2035, which could significantly impact long-term revenue projections.
• While Immunocore has demonstrated recent profitability and maintains a strong cash position, investors should continue to track KIMMTRAK's sales trajectory, R&D productivity, and the competitive landscape, particularly for pipeline assets like Brenentafusp in broader indications.